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Abstract The tumor microenvironment is the tissue that
determines the growth and progression of the tumor as well
as its ability to initiate metastases. The aim of the present
study has been to evaluate the role of RCAS1 in creating
the suppressive tumor microenvironment in cases of parotid
adenocarcinoma. The tissue samples of salivary gland
adenocarcinomas and their stroma and the palatine tonsils
which constituted the reference tissue sample group were
obtained during routine surgical procedures. The immuno-
reactivity of RCAS1, CD3, CD25, CD68, CD69, and
Foxp3 antigens was then evaluated by using the immuno-
histochemistry method. The patient’s consent was obtained
in each case. A statistically significantly higher RCAS1
immunoreactivity level was found in the adenocarcinoma
tissue samples in comparison to that found in the stromal
tissue samples. A statistically significantly higher RCAS1
immunoreactivity was also identified in the adenocarcino-
ma tissue samples derived from patients who had lymph
node metastases in comparison to patients without such
metastases. Additionally, we observed the presence of
RCAS1-positive macrophages in the stromal tissue sam-
ples. The infiltration of CD68-positive cells was signifi-
cantly stronger in the adenocarcinoma and stromal tissue
slides than in the reference group tissue slides; moreover,
the infiltration was a good deal more prominent in the
stromal tissue than in the adenocarcinoma tissue. The CD68
immunoreactivity levels in both the tumor and stromal
tissue samples were found to be significantly higher in
those patients who had lymph node metastases than in the
patients without such metastases. Additionally, the infiltra-
tion of CD3- and CD25-positive cells was more prominent
in the reference tissue slides than in the adenocarcinoma
and stromal tissue slides, and was stronger in the
adenocarcinoma tissue than in the stromal tissue. Further-
more, the infiltration of Foxp3-positive cells was seen
exclusively in the stroma whereas it was not even detected
in the adenocarcinoma tissue. Lastly, the Foxp3-positive cell
infiltration was more prominent in the stromal tissue than in
the reference group tissue. The present study demonstrates
that RCAS1 expression by both tumor cells and tumor-
associated macrophages may participate in creating the
immunosuppressive microenvironment in parotid gland
adenocarcinoma, thus promoting tumor development as well
as metastases.
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Introduction
The tumor microenvironment makes up the stroma of the
neoplasm and is the tissue that determines the growth and
progression of the tumor as well as its ability to initiate
metastases [1]. It has been established that the tumor
microenvironment inhibits the infiltration and activity of T
lymphocytes and creates local immunosuppression [2];
however, precisely which component of the tumor micro-
environment is responsible for tumor immunopathogeneity,
remains unknown [3]. The tumor microenvironment con-
sists of many distinct types of cells, including endothelial
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DOI 10.1007/s12307-010-0051-6cells and their precursors, pericytes, smooth muscle cells,
fibroblasts, carcinoma-associated fibroblasts, myofibro-
blasts, neutrophils, eosinophils, basophils, mast cells, T
and B lymphocytes, natural killer cells, and antigen-
presenting cells (APC) such as macrophages and dendritic
cells [4]. The creation of an immunosuppressive micro-
environment by the tumor enables the escape of tumor cells
from the host immunological surveillance and blocks any
effective anticancer immune response. Moreover, the range
of the tumor immunosuppressive activity is not just local
but general. The process is realized by many factors, such
as FasL and HLA-G; it is also realized either through
recruiting tumor-associated macrophages and Treg cells or
by the expression of yet other factors such as RCAS1.
RCAS1 is expressed by various cancer cells. The major
function of RCAS1 expression is to inhibit activated
immune cells such as T and B lymphocytes and NK cells
and the induction of the apoptosis of these cells. RCAS1 is
therefore responsible for tumor escape from the host
immunological surveillance and for the creation of immune
tolerance for tumor cells [5, 6]. It has also been postulated
that RCAS1 is involved in the remodeling of the tumor
microenvironment in cases of uterine cervical cancer.
Certainly, Sonoda et al. have demonstrated that RCAS1
expression is significantly related to VEGF expression and
microvessel density and through the regulation of angio-
genesis may participate in tissue remodeling [7]. In patients
with ovarian cancer, the level of RCAS1 expression was
inversely related to the presence of the vimentin-positive
cells in the stromal tissue, and it has therefore been
suggested that RCAS1 is involved in the remodeling of
the tumor microenvironment [7–9]. RCAS1 expression has
also been identified in the healthy portion of the micro-
environment of head and neck squamous cell carcinoma
and it has been a predictor of disease recurrence [10].
As both Treg cells and tumor-associated macrophages
seem to be involved in creating the suppressive tumor
microenvironment, the aim of our study has been to
determine the presence of these cells in salivary gland
adenocarcinomas and their stromas. We also focused on the
potential role of RCAS1 expression in the tumor micro-
environment of patients with salivary adenocarcinoma
relative to the presence of immune cells and their activity.
Materials and Methods
The Group of Patients
Patients with Salivary Adenocarcinoma
All the tissue samples were derived from patients from
whom salivary gland tumors were removed during surgery
performed in the Department of Otolaryngology of the
Jagiellonian University. The patient’s consent was obtained in
each case. Additionally, approval for the research program
was granted from the Ethical Committee of the Jagiellonian
University in Krakow: KBET/90/B/2005. We recruited 35
patients to our study from those who had undergone the
surgery between January 2000 and December 2007. All the
tissue samples were histopathologically verified. Pathological
analysis using the classical hematoxylin and eosin staining
techniques after fixation in a formalin of the surgically
removed material was performed in the Pathology Depart-
ment of the Jagiellonian University by an experienced
pathologist. The clinical characteristics of the subjects are
presented in Table 1.
Reference Group
We chose to use the palatine tonsils removed from patients
with recurrent tonsillitis as a reference tissue group. From
these samples we evaluated the epithelium lining of the
tonsils alone and not of the lymphoid tissue.
Immunohistochemical Analysis
Immunohistochemical analysis was performed in the
Pathology Department of the Jagiellonian University.
Five-micrometer slides from each case were stained to
visualize the expression of RCAS1, CD3-, CD25-, CD68-,
CD69, and Foxp3-positive cells. In all cases, immunohis-
tochemistry was performed by applying the Envision
method using Dako Autostainer. The following antibodies
were applied: mouse monoclonal antibody Anti- RCAS1
(Medical and Biological Laboratories, Naka-ku Nagoya,
Japan in DAKO Antibody Diluent with Background
Reducing Components-DAKO, Denmark, dilution
1:1000), monoclonal mouse antibody ImmunOTM (MP
Biomedicals, Inc., clone 1A12 in dilution 1:1000), CD68
(DAKO, clone PG-M1 in dilution 1:50), CD3 (Novocastra,
clone IF6 in dilution: 1:50), CD25 (Interleukin-2 Receptor,
NCL-CD25-305, Novocastra in dilution 1:25), and Foxp3,
according to the manufacturer’s instructions. Visualization
of the reaction products was performed using AEC (3-
amino-9-ethyl-carbazole) as a chromogen (AEC Substrate
Chromogen ready-to-use, DAKO, Denmark) for 10 min at
room temperature. Sections were then counterstained with
hematoxylin and mounted in glycergel. As a positive control,
a tonsil specimen was taken for RCAS1. All stainings were
performed with the same procedure except that the primary
antibody as a negative control was omitted. RCAS1
expression was evaluated in entire slides in the area of the
tumor and in the stroma, as follows: 0—no reactivity; +1—
weak, when observed any (also granular in paranuclear
region) cytoplasmic staining pattern (in up to 10% of positive
14 M. Dutsch-Wicherek et al.cells); +2—marked cytoplasmic (sometimes together with
membranous) staining in 11–30% of the cells); +3—high
expression (more than 30% of positive cells). Variable scales
were used to evaluate the amount of each type of cell semi-
quantitatively, depending on their overall number in the
specimen- an averagecell numberper1hpf(high power field,
objectivemagnificationx40).The average numberofCD25+,
CD3+, CD68+, and CD69+ cells were thus estimated as
follows: 0—lack of positive cells; +1—single positive cells in
thespecimen;+2—2-5positivecellsper1hpf;+3—morethan
5 positive cells/1hpf.
We were able to distinguish the macrophages from the
stromal cells by their respective morphologies, that is, their
characteristic size, nuclear-cytoplasmic ratio, and cell
nucleus picture.
Statistical Analysis The distribution of variables in the study
groups of patients checked with the use of the Shapiro-Wilk
test showedthateachofthepatientswasinfact differentfrom
normal. The statistical significance between the groups was
determined by the Kruskal-Wallis test, one-way analysis of
variance by ranks. The Mann-Whitney U test was then used
as applicable. All statistical analyses were carried out with
the Statistica 8.0 software program. A p value<0.05 was
considered indicative of statistical significance.
Results
The Immunoreactivity of Antigens in Adenocarcinomas
and Their Stroma
The Analysis of CD3 and CD25 Immunoreactivity
in the Tissue Slides Examined
CD3 antigen immunoreactivity was found in 77.2% of the
adenocarcinoma samples and in 8% of the stromal samples
(Fig. 1a). CD25 antigen immunoreactivity was demonstrated
in 31.4% of the adenocarcinoma tissue slides and in 2.8% of
the stromal slides; it was also observed in salivary gland
secretions (Fig. 1b).
The Analysis of CD68 Immunoreactivity in the Tissue
Slides Examined
CD68 antigen immunoreactivity was demonstrated in 20%
of the adenocarcinoma tissue slides and in 30% of the
stromal tissue slides (Fig. 2).
The Analysis of CD69 Immunoreactivity in the Tissue Slides
Examined
CD69 antigen immunoreactivity was demonstrated in 2.8%
of the adenocarcinoma tissue slides and in 5% of the
stromal tissue slides (Fig. 3).
The Analysis of RCAS1 Immunoreactivity in the Tissue
Samples Examined
RCAS1 antigen immunoreactivity was identified in 65.7%
of the adenocarcinoma tissue slides and in 14.2% of the
stromal tissue slides (Fig. 4).
We also discovered that the macrophages infiltrating the
stroma were expressing RCAS1 (Fig. 5).
Table 1 The clinical characteristics of the patients with salivary
adenocarcinomas
The number of patients 35
M
a 14
W
a 21
Age range (average) 12–80 (55.9)
M
a 31–80 (56.9)
W
a 12–79 (55.2)
Tumor stage
b
I–II 29
III–IV 6
The presence of lymph node metastases
N0 29
N+ 6
Tumor size
T1–T2 32
T3–T4 3
Tumor grade
G1 2
G2 24
G3 9
Localization of the tumor
Parotid gland 30
Nasal cavity 2
Oral cavity 2
Orbit 1
Histological types of tumors
Adenocarcinoma 13
Adenocarcinoma acinocellulare 16
Adenocarcinoma apocrinale 2
Adenocarcinoma mucinosum 1
Adenocarcinoma tubulare 1
Adenocarcinoma basaloides 1
Adenocarcinoma gelatinosum 1
Tumors
Primary 30
Recurrence 5
aM men; W women
bTumorstagewasevaluatedaccordingtoTNMclassification6thedition,2002
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of the Antigens Analyzed in Adenocarcinoma
and Their Stromas
The results obtained regarding the immunoreactivity of the
antigens analyzed in the tissue samples of adenocarcinomas
and their stromas are presented in Table 2.
A statistically significantly higher number of CD3- and
CD25-positive cells were identified in the adenocarcinoma
tissue slides than in the stromal slides. In turn, a statistically
significantly higher number of CD68-positive cells were
identified in the tumor microenvironment than in the tumor
tissue slides. The immunoreactivity of the Foxp3 antigen
was not identified in the adenocarcinoma tissue, but was
observed exclusively in the lymphocytes of the stromal
tissue.
The Comparison of Antigen Immunoreactivity
in the Adenocarcinoma and Reference Group
Tissue Slides
The results obtained are presented in Table 3.
The Comparison of the Levels of Antigen Immunoreactivity
in the Stroma and Reference Group Tissues
The results obtained are presented in Table 4.
The analysis of antigen immunoreactivity with respect to
tumor grade and size did not reveal any significant
differences.
The analysis of the levels of antigen immunoreactivity in
patients with regional lymph node metastases revealed
significant differences. The results obtained are presented in
Table 5.
Fig. 3 The immunoreactivity of CD69 antigen immunoreactivity in
adenocarcinoma and stromal tissue slides
Fig. 2 The immunoreactivity of CD68 in adenocarcinoma and
stromal tissue slides
Fig. 1 The immunoreactivity of
CD3 and CD25 antigens in
adenocarcinoma and stromal
tissue slides
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In the present study statistically significantly higher levels
of RCAS1 immunoreactivity were identified in the adeno-
carcinoma tissue samples derived from patients who had
lymph node metastases in comparison to the levels found in
the tissues from patients without such metastases. To our
knowledge this is the first investigation concerning RCAS1
expression in salivary gland tumors and their stromas. Our
observation coincides with what has been presented in other
reports on the expression of RCAS1 in patients with head
and neck squamous cell carcinoma, where RCAS1 expres-
sion was significantly higher in patients with the presence
of lymph node metastases and was identified as higher in
cases where the extra-capsular spread of infiltrated lymph
nodes was observed [10, 11]. The relation between RCAS1
expression and the presence of lymph node metastases was
observedinmanymalignantneoplasms(includingesophageal,
gastric, gallbladder, pancreatic, colon and uterine cervix)
[7, 12–17]. The major function of RCAS1 expression is to
inhibit activated immune cells such as T and B lympho-
cytes and NK cells and to induce their apoptosis; RCAS1
would therefore be responsible for tumor escape from the
host immunological surveillance and the creation of
immune tolerance for tumor cells [5, 6]. It has also been
postulated that RCAS1 maybe involved in tumor micro-
environment remodeling in cases of uterine cervix cancer
[7, 9]. In cases of cervical cancer, RCAS1 expression has
been associated with VEGF expression and microvessel
density in a statistically significant way; it has therefore
been proposed that RCAS1 maybe involved in the control
of angiogenesis [7]. In the present study we also observed
the level of mmunoreactivity of RCAS1 in the stroma of
adenocarcinoma and it was statistically significantly lower
than the level of RCAS1 immunoreactivity observed in the
cancer tissue samples. RCAS1 immunoreactivity in the
stromal samples was significantly higher in patients who
had lymph node metastases in comparison to those patients
without such metastases. This observation coincides with
the observations presented in our previous report on the
stroma of squamous cell carcinoma of the head and neck.
RCAS1 has been detected not only in cancer cells, but also
Fig. 5 RCAS1 -positive macrophages in adenocarcinoma and in its
stroma
Fig. 4 RCAS1 immunoreactivity
in adenocarcinoma and stromal
tissue slides
Table 2 The levels of CD3, CD25, CD68, CD69, Foxp3, RCAS1
antigen immunoreactivity in the adenocarcinoma and stromal tissue
slides
Antigen Adenocarcinoma
Median (IQR)
Stroma Median
(IQR)
p value
CD3 1.37 (2.0) 0.25 (0) p<0.001
CD25 0.42 (0) 0.05 (0) p<0.001
CD68 0.57 (0) 0.74 (0) 0.01
CD69 0.11 (0) 0.08 (0) NS
Foxp3 0 (0) 0.22 (0) NS
RCAS1 1.62 (2) 0.4 (0) p<0.001
IQR Interquarter Range; NS Non-statistically Significant
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as the stroma and the epithelium adjacent to the tumor.
Moreover, RCAS1 stromal expression has been associated
with a higher risk of local recurrence of the disease [10].
There are two activities involving RCAS1 expression
that seem to be important in tumor development. One
activity is related to its participation in maintaining indolent
chronic inflammation in the tumor and its healthy stroma
which promotes tumor growth [18]. The second activity of
RCAS1 helps to create immune tolerance against tumor
antigens, including the elimination of the proper immune
anticancer response, by inhibiting the activated T and B
lymphocytes and NK cells and inducing their apoptosis [5].
Additionally, the immunoregulatory role of RCAS1 does
not just affect the tumor and its microenvironment, but can
have systemic consequences as well. RCAS1 can be
secreted in a soluble form, sRCAS1, by ectodomain
shedding and has been identified in the blood sera of
patients with head and neck squamous cell carcinoma,
adenocarcinoma, and benign tumors such as mixed tumor
[19–21]. The level of sRCAS1 was statistically significantly
higher in patients with malignant tumors than in those
with benign tumors [19, 20, 22, 23]. A higher sRCAS1
blood serum level has been identified in patients who had
lymph node metastases than in those without such
metastases, as well as in patients with malignant gastro-
esophageal tract tumors, uterine cervix tumors, head and
neck squamous cell carcinomas, and salivary gland adeno-
carcinomas [20, 24]. Furthermore, the sRCAS1 blood
serum level was seen to decrease in patients following
radical surgery and to increase in patients suffering from
cancer relapse [20].
In the present study we observed that the infiltration of
CD3- and CD25-positive cells was more prominent in the
reference group tissue sample slides than in the adenocar-
cinoma and stromal tissue slides; it was also found to be
stronger in adenocarcinoma than in the stromal slides.
IL-2Rα (CD25) is a basic receptor for the proliferation
of T lymphocytes and its decreased expression may induce
immune suppression [25]. TIL (tumor infiltrating lympho-
cytes) are present in most solid tumors and their micro-
environments and most commonly consist of CD3-positive
T lymphocytes. The specific TIL-mediated tumor cytolysis
has been demonstrated in cases of breast cancer, indicating
that IL-2 maybe the trigger for this response [26]. Such a
cytolysis has also been observed in patients with malignant
Table 3 The comparison of the levels of antigen immunoreactivity in
adenocarcinoma and the tissue reference group. Table 3 presents the
results of the analysis of the immunoreactivity of the antigens in the
adenocarcinoma and reference tissue slides. The results obtained were
non-parametric and so the Mann-Whitney’s test was used for the
statistical analysis; p<0.05 was accepted as statistically significant.
The results are presented as median and interquarter range (IQR)
values. The immunoreactivity of the antigens was evaluated according
to the scale presented in the Methods section
Antigen Adenocarcinoma
Median (IQR)
Reference group
Median (IQR)
p value
CD3 1.3 (2) 1.5 (2) 0.0008
CD25 0.42 (0) 2.4 (3) p<0.001
CD68 0.57 (0) 0.1 (0) p<0.001
CD69 0.11 (0) 0 (0) p<0.001
Foxp3 0 (0) 0 (0) p<0.001
RCAS1 1.62 (2) 2.4 (3) NS*
IQR Interquarter Range; NS Non-statistically Significant
Table 4 The comparison of the levels of antigen immunoreactivity in
the stromal and reference tissue samples. Table 4 presents the results
of the analysis of the immunoreactivity of the antigens in the stroma
and reference tissue slides. The results obtained were non-parametric
and so the Mann-Whitney’s test was used for the statistical analysis;
p<0.05 was accepted as statistically significant. The results are
presented as median and interquarter range (IQR) values. The
immunoreactivity of the antigens was evaluated according to the scale
presented in the Methods section
Antigen Stroma Median
(IQR)
Reference group
Median (IQR)
p value
CD3 0.25 (0) 1.5 (2) p<0.001
CD25 0.05 (0) 2.4 (3) p<0.001
CD68 0.74 (0) 0.1 (0) 0.01
CD69 0.08 (0) 0 (0) 0.04
Foxp3 0.22 (0) 0 (0) NS
RCAS1 0.4 (0) 2.4 (3) p<0.001
IQR Interquarter Range; NS Non-statistically Significant
Table 5 Analysis of the immunoreactivity of CD3, CD25, CD68,
CD69, Foxp3, and RCAS1 antigens in the adenocarcinoma and
stromal tissue slides in patients with regional lymph node metastases
(N + group) and in patients without metastases (N0 group)
Antigen N0 (n=29)
Median (IQR)
N+ (n=6)
Median (IQR)
p value
CD3 Tumor 1.0 (1.0) 1.0 (1.0) NS
CD3 Stroma 0 (1) 0 (1) NS
CD25 Tumor 0 (1) 0 (1) NS
CD25 Stroma 0 (1) 0 (1) NS
CD68 Tumor 0 (1) 1 (1) 0.03
CD68 Stroma 0 (1) 2 (1) 0.02
CD69 Tumor 0 (0) 0 (0) NS
CD69 Stroma 0 (0) 0 (0) NS
Foxp3 Tumor 0 (0) 0 (0) NS
Foxp3 Stroma 0 (0) 0 (0) NS
RCAS1 tumor 1 (1) 2 (1) p<0.001
RCAS1 Stroma 0 (0) 0 (0) 0.03
IQR Interquarter Range; NS Non-statistically Significant
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stimulation.IL-2activatesTlymphocytesaftertheinteraction
with IL-2 (IL-2R) on the surface of T lymphocytes [27, 28].
In the microenvironment of breast cancer TIL lymphocytes
were activated (expressed CD69, CD43, and CD38), but
were typified by significantly decreased IL-2R expression
(decreased expression of CD25 antigen). Additionally, the
production and secretion of IL-2 was decreased or absent in
the breast cancer microenvironment [29]. Thus, the decreased
expression of CD25 as well as IL-2 may result from the
induction of the immune tolerance in the tumor microenvi-
ronment [30]. In sum, we observed the presence of TIL with
the immunoreactivity of CD3, in both the adenocarcinoma
and stromal tissue samples. These cells were activated (CD69
antigen immunoreactivity was significantly higher in the
adenocarcinomaandstromaltissuethaninthereferencegroup
tissue) but their cytotoxic function was impaired as indicated
by decreased CD25 antigen immunoreactivity. This observa-
tion seems to confirm the presence of selectively inhibited
lymphocytes within the neoplasm and its microenvironment.
Such a profile of CD69- and CD25-antigen expression has
been observed by Sheu et al. and has been identified as a
phenotype of selectively suppressed lymphocytes infiltrating
the tumor and its microenvironment [31].
The immune tolerance to the tumor antigens is created
by proteins and cells. Tumor- associated macrophages
significantly outnumber the antigen-presenting cells in
solid tumors [32–35]. It has further been demonstrated that
tumor-associated macrophages may promote tumor growth
and metastases [32–35]. In our study we observed a
significantly higher number of CD68-positive cells (macro-
phages) in both the adenocarcinoma and the stromal tissue
samples than in the tissue samples of the control group.
Furthermore, the number of CD68-positive cells in adeno-
carcinoma and stromal tissue was higher in those patients
who had lymph node metastases than in the patients
without such metastases. The positive correlation between
tumor-associated macrophages and poor prognosis has been
demonstrated in cases of many types of cancer, and these
macrophages were present from the early stages of tumor
development [33, 35, 36]. The tumor and its environment
express chemotactic agents for macrophages [37]; macro-
phages in turn secrete growth factors and angiogenic factors
which are able to modify the tumor microenvironment and
affect tumor growth [35, 38, 39]. Additionally, in our study
the macrophages were found to exhibit RCAS1 immuno-
reactivity. RCAS1-expressing macrophages have also been
observed in the bone marrow where they play a pivotal role in
the regulation of the process of erythropoiesis by eliminating
improper cells byinducing their apoptosis [39, 40]. It has been
demonstrated that macrophages stimulated with LPS (lipo-
polysacharide) enhance RCAS1 expression and induce
apoptosis of the progenitor cells of erythroblast line through
RCAS1 [39]. It has further been shown that RCAS1 can only
be identified on activated monocytes [40]. Interestingly,
RCAS1 expression has been detected on macrophages in
various types of inflammatory liver diseases. The type of
macrophage found in the inflamed tissue depends on the
particular stage of inflammation. At the beginning stages of
inflammation, macrophages act as antigen-presenting cells.
At more advanced stages, macrophages start to express
different types of antigens, such as RCAS1, and their function
becomes immunosuppressive [41]. In addition, the presence
of RCAS1-positive macrophages has been demonstrated in
the microenvironment of nasal polyps with extensive
inflammation [42, 43]. Because RCAS1-positive macro-
phages represent a cell population able to negatively regulate
the activity of immune system cells, their presence in the
tumor microenvironment may also contribute to creating local
immunosuppression in both the tumor and its microenviron-
ment by inhibiting activated lymphocytes that possess
RCAS1R (namely, T and B lymphocytes and NK cells).
The immune tolerance to tumor growth is also realized
by the recruitment of T regulatory (Treg) cells to the tumor
and its microenvironment. For instance, Treg cells are able
to suppress proliferating effector T lymphocytes [44, 45]. In
order to explore the tumor microenvironment and to be able
to localize both the antigens expressed by the cells and the
cells themselves, we performed immunohistochemistry. This
method, however, did not enable us to evaluate the type of
cell precisely (we could assess the immunoreactivity of only
one antigen for the tissue slide); it was therefore not possible
to identify Treg cells within the tumor and its microenviron-
ment. We have, however, observed Foxp3-expressing lym-
phocytes exclusively in tumor stroma, and the number of
these cells was significantly higher in the stroma than in the
reference group tissue. If the cells represented Treg cells it
would indicate enhanced Treg cell infiltration within the
tumor microenvironment. These cells would then be respon-
sible for creating the local immunosuppressive microenvi-
ronment in the stroma that inhibits the response of Teffector
cells. Lastly, it was shown that these cells interact with
macrophages as IL-10 triggers the expression of B7-H4
antigen and the B7-H4-positive macrophages exert an
immunosuppressive effect similar to that of Treg cells [2].
In conclusion, we have demonstrated in this study that
RCAS1 expression by tumor cells and tumor-associated
macrophages within the tumor microenvironment when
coupled with a both a decreased number of CD3-positive
cells and the presence of Foxp3-positive lymphocytes, may
participate in creating the immunosuppressive microenvi-
ronment in salivary gland adenocarcinomas.
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